Familial Chylomicronemia
2
Pipeline Programs
1
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
REDEMPLOApproved
plozasiran
Arrowhead PharmaceuticalsAPOC-III-directed RNA Interaction [EPC]subcutaneous2025
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Arrowhead PharmaceuticalsPASADENA, CA
2 programs1
1
PlozasiranPhase 31 trial
PlozasiranN/A1 trial
Active Trials
NCT06796426Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Arrowhead PharmaceuticalsPlozasiran
Clinical Trials (2)
Total enrollment: 75 patients across 2 trials
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Start: Dec 2021Est. completion: Apr 202675 patients
Phase 3Active Not Recruiting
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space